3. Results
allergy
PATHOLOGY, ALLERGY, SEASONAL ALLERGIC RHINITIS
Overall, a total of 108 participants presenting with seasonal allergic rhinitis were randomised from the 23 September 2019 to the 11 February 2022. Of the randomised participants, 101 (92.5%) otherwise healthy male and female participants aged between 21 and 77 years completed the study (No significant difference was seen between the Levagen+ and placebo groups for the allergy symptoms scores (rTNSS) at baseline or throughout the 14 days of treatment (No significant difference was seen between the groups for the total RQLQ score from baseline to week 2 (The sub-group analysis conducted on the participants scoring over four on the total rTNSS weekly score (n = 79) showed a significant reduction in both groups over the two weeks, with a significant difference between the groups at week 2 of treatment (Due to the COVID-19 pandemic, not all the participants were able to attend the clinic for pathology testing. The results presented are for the participants who were able to complete both baseline and final blood draws (n = 36). A significant difference was seen between groups for the change in plasma histamine concentration (